INSPIRE: INnovative SABR for Prostate Cancer All IREland
ConditionProstate Adenocarcinoma
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexMale
Age18+
SponsorCancer Trials Ireland
About this trial
This is a Phase II, single arm, multi-centre, prospective clinical trial evaluating next generation Stereotactic Ablative Radiotherapy (SABR) for low, intermediate, and eligible high-risk prostate cancer. Eligible patients will receive next generation prostate SABR incorporating toxicity reduction strategies
Eligibility criteria
Qualifiers
Written informed consent obtained prior to any study-related procedures
Males ≥ 18 years of age
ECOG performance status (PS) 0-2
Biopsy-proven prostate adenocarcinoma without neuro-endocrine differentiation (within 18 months prior to registration, unless on active surveillance and re-biopsy not clinically indicated)
Disqualifiers
Previous malignancy within the last 2 years (except basal cell carcinoma (BCC) or squamous carcinoma of the skin), or if previous malignancy is expected to significantly compromise 5 year survival
Prior pelvic radiotherapy
Any prior active treatment for prostate cancer (with the exception of ADT). Patients previously on active surveillance are eligible if they continue to meet all other eligibility criteria.
Life expectancy <5 years.
Trial design
Treatments tested in this trial
- Next generation Stereotactic Ablative Radiotherapy (SABR)
Treatment groups
136 Participants
are divided into 1 treatment groupLocations
3Ireland
St Luke's Centre for Radiation Oncology at Beaumont HospitalD09 FT51, DublinLeinster, Ireland
Bon Secours - UPMC HillmanT12 DV56, Cork Ireland
United Kingdom
Northern Ireland Cancer Centre (NICC)BT9 7AB, BelfastUlster, United Kingdom
Sponsors and collaborators
Cancer Trials Ireland
Lead sponsor
Source ClinicalTrials.gov